148 related articles for article (PubMed ID: 31099252)
1. Antiretroviral Activity of AMD11070 (An Orally Administered CXCR4 Entry Inhibitor): Results of NIH/NIAID AIDS Clinical Trials Group Protocol A5210.
Johnson VA; Cramer YS; Rosenkranz SL; Becker S; Klingman KL; Kallungal B; Coakley E; Acosta EP; Calandra G; Saag MS;
AIDS Res Hum Retroviruses; 2019 Aug; 35(8):691-697. PubMed ID: 31099252
[TBL] [Abstract][Full Text] [Related]
2. Proof of activity with AMD11070, an orally bioavailable inhibitor of CXCR4-tropic HIV type 1.
Moyle G; DeJesus E; Boffito M; Wong RS; Gibney C; Badel K; MacFarland R; Calandra G; Bridger G; Becker S;
Clin Infect Dis; 2009 Mar; 48(6):798-805. PubMed ID: 19193109
[TBL] [Abstract][Full Text] [Related]
3. The molecular pharmacology of AMD11070: an orally bioavailable CXCR4 HIV entry inhibitor.
Mosi RM; Anastassova V; Cox J; Darkes MC; Idzan SR; Labrecque J; Lau G; Nelson KL; Patel K; Santucci Z; Wong RS; Skerlj RT; Bridger GJ; Huskens D; Schols D; Fricker SP
Biochem Pharmacol; 2012 Feb; 83(4):472-9. PubMed ID: 22146583
[TBL] [Abstract][Full Text] [Related]
4. Anti-HIV small-molecule binding in the peptide subpocket of the CXCR4:CVX15 crystal structure.
Cox BD; Prosser AR; Katzman BM; Alcaraz AA; Liotta DC; Wilson LJ; Snyder JP
Chembiochem; 2014 Jul; 15(11):1614-20. PubMed ID: 24990206
[TBL] [Abstract][Full Text] [Related]
5. Hologram quantitative structure activity relationship, docking, and molecular dynamics studies of inhibitors for CXCR4.
Zhang C; Du C; Feng Z; Zhu J; Li Y
Chem Biol Drug Des; 2015 Feb; 85(2):119-36. PubMed ID: 24923360
[TBL] [Abstract][Full Text] [Related]
6. HIV co-receptors as targets for antiviral therapy.
Schols D
Curr Top Med Chem; 2004; 4(9):883-93. PubMed ID: 15134547
[TBL] [Abstract][Full Text] [Related]
7. Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals.
Irlbeck DM; Amrine-Madsen H; Kitrinos KM; Labranche CC; Demarest JF
AIDS; 2008 Jul; 22(12):1425-31. PubMed ID: 18614865
[TBL] [Abstract][Full Text] [Related]
8. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211.
Wilkin TJ; Su Z; Kuritzkes DR; Hughes M; Flexner C; Gross R; Coakley E; Greaves W; Godfrey C; Skolnik PR; Timpone J; Rodriguez B; Gulick RM
Clin Infect Dis; 2007 Feb; 44(4):591-5. PubMed ID: 17243065
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication.
Skerlj RT; Bridger GJ; Kaller A; McEachern EJ; Crawford JB; Zhou Y; Atsma B; Langille J; Nan S; Veale D; Wilson T; Harwig C; Hatse S; Princen K; De Clercq E; Schols D
J Med Chem; 2010 Apr; 53(8):3376-88. PubMed ID: 20297846
[TBL] [Abstract][Full Text] [Related]
10. Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection.
Hendrix CW; Collier AC; Lederman MM; Schols D; Pollard RB; Brown S; Jackson JB; Coombs RW; Glesby MJ; Flexner CW; Bridger GJ; Badel K; MacFarland RT; Henson GW; Calandra G;
J Acquir Immune Defic Syndr; 2004 Oct; 37(2):1253-62. PubMed ID: 15385732
[TBL] [Abstract][Full Text] [Related]
11. The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen.
Waters L; Mandalia S; Randell P; Wildfire A; Gazzard B; Moyle G
Clin Infect Dis; 2008 May; 46(10):1617-23. PubMed ID: 18419499
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia.
Hunt PW; Harrigan PR; Huang W; Bates M; Williamson DW; McCune JM; Price RW; Spudich SS; Lampiris H; Hoh R; Leigler T; Martin JN; Deeks SG
J Infect Dis; 2006 Oct; 194(7):926-30. PubMed ID: 16960780
[TBL] [Abstract][Full Text] [Related]
13. Role of CXCR4 in cell-cell fusion and infection of monocyte-derived macrophages by primary human immunodeficiency virus type 1 (HIV-1) strains: two distinct mechanisms of HIV-1 dual tropism.
Yi Y; Isaacs SN; Williams DA; Frank I; Schols D; De Clercq E; Kolson DL; Collman RG
J Virol; 1999 Sep; 73(9):7117-25. PubMed ID: 10438797
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of HIV Fusion by Small Molecule Agonists through Efficacy-Engineering of CXCR4.
Berg C; Daugvilaite V; Steen A; Jørgensen AS; Våbenø J; Rosenkilde MM
ACS Chem Biol; 2018 Apr; 13(4):881-886. PubMed ID: 29461034
[TBL] [Abstract][Full Text] [Related]
15. A Novel CXCR4 Targeting Protein SDF-1/54 as an HIV-1 Entry Inhibitor.
Tan S; Li W; Li Z; Li Y; Luo J; Yu L; Yang J; Qiu M; Cheng H; Xu W; Jiang S; Lu L; Liu S; Ma W
Viruses; 2019 Sep; 11(9):. PubMed ID: 31540474
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of HIV infection by CXCR4 and CCR5 chemokine receptor antagonists.
De Clercq E; Schols D
Antivir Chem Chemother; 2001; 12 Suppl 1():19-31. PubMed ID: 11594685
[TBL] [Abstract][Full Text] [Related]
17. Safe use of the CXCR4 inhibitor ALX40-4C in humans.
Doranz BJ; Filion LG; Diaz-Mitoma F; Sitar DS; Sahai J; Baribaud F; Orsini MJ; Benovic JL; Cameron W; Doms RW
AIDS Res Hum Retroviruses; 2001 Apr; 17(6):475-86. PubMed ID: 11350661
[TBL] [Abstract][Full Text] [Related]
18. A Membrane-Anchored Short-Peptide Fusion Inhibitor Fully Protects Target Cells from Infections of Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
Tang X; Jin H; Chen Y; Li L; Zhu Y; Chong H; He Y
J Virol; 2019 Nov; 93(22):. PubMed ID: 31462566
[TBL] [Abstract][Full Text] [Related]
19. HIV chemokine receptor inhibitors as novel anti-HIV drugs.
Princen K; Schols D
Cytokine Growth Factor Rev; 2005 Dec; 16(6):659-77. PubMed ID: 16005254
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of CXCR4-CXCL12 chemotaxis in melanoma by AMD11070.
O'Boyle G; Swidenbank I; Marshall H; Barker CE; Armstrong J; White SA; Fricker SP; Plummer R; Wright M; Lovat PE
Br J Cancer; 2013 Apr; 108(8):1634-40. PubMed ID: 23538388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
